Trials / Terminated
TerminatedNCT05511844
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Orum Therapeutics USA, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors. The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ORM-5029 | Intravenous infusion |
Timeline
- Start date
- 2022-10-03
- Primary completion
- 2025-06-02
- Completion
- 2025-06-02
- First posted
- 2022-08-23
- Last updated
- 2025-07-04
Locations
11 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05511844. Inclusion in this directory is not an endorsement.